Vera Therapeutics schedules ORIGIN 3 webcast: USD 34 target for Vera Therapeutics stock

Published on 10/21/2026 at 02:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Leerink set a USD 34 target for Vera Therapeutics stock on October 12, 2026. ORIGIN 3 data webcast is set for October 22.

Upcoming clinical milestones

Vera Therapeutics scheduled two investor webcasts on October 20, 2026.
Five company-sponsored abstracts are set for ASN Kidney Week on October 2, 2026.
Leerink initiated coverage with a USD 34 target on October 12, 2026.

VERA, US92337R1014, Illustration mit AI erstellt.

Vera Therapeutics (ISIN US92337R1014) scheduled two investor webcasts on October 20, 2026, including an October 22 presentation of final ORIGIN 3 data. The update gives Vera Therapeutics stock a near-term clinical milestone and a separate USD 34 analyst target from Leerink.

Two webcasts set the timetable

According to GlobeNewswire, Vera will host an investor webcast at 4:30 p.m. ET on October 22, 2026, to discuss the final efficacy analysis from the ORIGIN 3 trial of TRUTAKNA in IgA nephropathy. The same release scheduled a second webcast for third quarter 2026 financial results on November 5, 2026, also at 4:30 p.m. ET.

What does the target mean for Vera?

Markets Insider reported on October 12, 2026, that Leerink initiated coverage with a Market Perform rating and a USD 34 price target. Leerink modeled peak IgA nephropathy sales at USD 1.8 billion, below its stated consensus comparison of USD 3.1 billion, making commercial uptake a central valuation variable.

Three dated clinical milestones

On September 15, 2026, Vera reported two-year ORIGIN 3 efficacy findings for TRUTAKNA in IgA nephropathy, according to the company's investor-relations page. On October 2, 2026, Vera Therapeutics said five sponsored abstracts would be presented at ASN Kidney Week. The October 20 webcast announcement is the latest of the three events.

Next dates for investors

The next company event is the ORIGIN 3 webcast on October 22, 2026, followed by the third quarter 2026 results webcast on November 5, 2026. The October 22 session will include a question-and-answer segment with management and Jonathan Barratt of the University of Leicester.

Clinical evidence drives the setup

Vera is a commercial-stage biotechnology company focused on autoimmune diseases, with TRUTAKNA as its flagship product for primary IgA nephropathy. The October presentations and November results date place clinical evidence and early commercial execution at the center of the stock narrative.